Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis and an increased risk of transformation. Few effective therapies are available for lower risk MDS patients, especially after the failure of hypomethylating agents. MDS progenitor cells are dependent on the nuclear factor-jB (NF-jB) for survival, which makes it an attractive therapeutic target. As a proteosomal inhibitor, bortezomib is thought to have inhibitory activity against NF-jB. We designed a proof-of-principle study of subcutaneous (SC) bortezomib in lower risk MDS patients with evidence of NF-jB activation in their bone marrow. Fifteen patients were treated, their median age was 71 (range 56-87), 33% were low and 67% int-1 by IPSS, median number of prior therapies was 2, all patients were transfusion dependent. Baseline median pp65 percentage was 31% and 11 patients had evidence of ring sideroblasts (RS). SC bortezomib was safe, well tolerated with no excess toxicity. Three patients out of the 15 (20%) had evidence of response with hematologic improvement (HI-E). Bortezomib caused a decrease in pp65 levels in 7 out of 13 evaluable patients (54%, P 5 .025). Of interest, unexpectedly, we observed a significant decrease in RS in 7 out of 10 (70%) evaluable patients during treatment. In conclusion, this study suggests that NF-jB activation, measured by pp65 levels, may be a useful biomarker in MDS. Bortezomib is safe in this patient population but has modest clinical activity. The role of the proteasome in the genesis of RS needs further study.
| I N T R O D U C T I O N
Myelodysplastic syndromes (MDS) represent a spectrum of clonal hematopoietic disorders that affect the myeloid lineage, characterized by ineffective hematopoiesis and an increased risk of transformation to acute myeloid leukemia (AML). 1 Patients with MDS are stratified into lower or higher-risk categories based on IPSS or IPSS-R classifications. 2, 3 For a majority of lower risk (low or int-1) MDS patients, the standard of care
remains suboptimal with few effective therapeutic alternatives, particularly for patients previously treated with a hypomethylating agent (HMA). 4 Novel treatment approaches are needed for these patients.
Accumulating evidence from recent clinical and molecular studies supports a key role for deregulation of the innate immune system and inflammatory signaling in the pathogenesis of MDS. 5 Toll-like receptors (TLRs) are a family of pattern-recognition receptors that play a pivotal role in the innate immunity. These receptors activate a common signaling pathway through adaptor protein MyD88, culminating in the activation of nuclear factor-kB (NF-jB). 6, 7 Recent studies in MDS demonstrated a constitutive activation of genes that involve a variety of different steps of this pathway. [8] [9] [10] [11] This evidence implicates NF-jB in the pathogenesis of MDS, and, hence, makes it a potential therapeutic target.
The NF-jB transcription factor family is composed of five proteins (p50, p52, p65, c-Rel, and RelB) that play a role in apoptosis regulation, cell proliferation, survival, and metastasis. 12 It is, therefore, not surprising that it has been linked to the pathogenesis of multiple solid and hematologic malignancies. [12] [13] [14] [15] Within the canonical pathway, members of the NF-jB family form dimers (most commonly heterodimers of p65 with p50) which are retained in the cytoplasm through interactions with inhibitory molecules of the inhibitor of the NF-jB (IjB) family. 12, 16 Activating stimuli (including cytokines and various stress signals) lead to phosphorylation of the IjB molecules by IjB kinases (IKKs) and their degradation via the ubiquitin-proteasome pathway. 17 Consequently, the NF-jB dimers are liberated and are then free to translocate to the nucleus and activate their target genes. 18 Phosphorylation of p65 is required for nuclear translocation and transcriptional activation of target genes involved in proliferation, stress response and cytokine production. 19, 20 Therefore, phosphorylated p65 (pp65) may be used as a clinical surrogate for NF-jB activation.
The NF-jB subunit RelA/p65 has also been described as an important factor in hematopoiesis through the regulation of hematopoietic stem cell function and lineage commitment. In addition, p65 has been shown to play a potential role in the regulation of cell differentiation via up-regulation of additional NF-jB subunits; suggesting that, p65 may influence specific lineage-committed cell types. 21, 22 Bortezomib is a reversible selective inhibitor of the 26S proteosomal subunit with previously described inhibitory activity against NFjB. [23] [24] [25] In preclinical and clinical studies, bortezomib was shown to induce apoptosis in malignant cells of hematopoietic lineage via inhibition of the NF-jB pathway. 26, 27 Leukemic stem cells are highly dependent on NF-jB for survival 28, 29 ; MDS progenitors are also highly dependent on NF-jB activation for survival. 10, 30 In vitro studies of MDS cells have shown that NF-jB inhibition leads to an autophagic stress response followed by apoptotic cell death. 31 In clinical studies, bortezomib has shown modest activity in myeloid neoplasms, both as a single agent and in combination with other cytotoxic agents. [32] [33] [34] [35] [36] Comparison between subcutaneous (SC) and intravenous administration of bortezomib showed that SC administration offers similar efficacy, with improved safety profile, especially with a significantly lower risk of peripheral neuropathy. 37, 38 As a proof of concept, we designed this study using SC bortezomib in patients with low or intermediate-1 risk MDS who had evidence of NF-jB activation. Our objectives were primarily to determine the effect of SC bortezomib on modulation of NF-jB activity and secondarily to determine the clinical activity, safety, and tolerability of SC bortezomib in these patients. 
| P A T I E NT S A ND M E T H O DS

| Eligibility criteria
| Correlative studies
We analyzed phosphorylated-p65 (pp65) level at baseline on day 21 of . 42 Positive results were defined as nuclear fluorescence phosphorylated p65 NF-jB in at least 5% of BM cells.
| Cytogenetic studies
Conventional chromosomal analysis was performed on G-banded metaphases that were prepared from unstimulated 24 and 48-h BM aspirate cultures using standard techniques. The results were reported using the 2016 International System for Human Cytogenetics Nomenclature as described previously.
43,44
| Molecular studies
We performed mutation analysis using a 28-gene panel as previously described. [45] [46] [47] [48] as a reference. For clinical reporting, a minimum sequencing coverage of 3250 (bidirectional true paired-end sequencing) was required. The analytical sensitivity was established at 5% mutant reads in a background of wild-type reads. CEBPA was performed using PCR followed by Sanger sequencing. Internal tandem duplications of FLT3 gene and NPM1 mutation (exon12) were assessed using PCR followed by capillary electrophoresis (all of these methods have been previously described). 45, 49, 50 PCR-based DNA sequencing was then used to identify: RAS mutation (codons 12, 13, and 61 of the KRAS and NRAS), IDH1R132 mutation (codon 87 to 138 in exon 4), IDH2 mutation (exon 4), and c-KIT mutation (exon 17) as previously described. 
| Statistical considerations
The primary objective of the study was to investigate the effect of SC an OR rate of about 15% was worth considering. We assumed the OR rate had a prior Beta distribution (0.3, 1.7) with mean of 0.15 and variance of 0.0425. The study was to be discontinued prematurely if at any time we determined that there was a >95% chance that the average OR rate was <15%. The proportion of patients having hematologic improvement and the proportion of patients having grade 3 or higher toxicities were estimated by a Bayesian posterior credible interval. Survival probabilities were calculated by using the Kaplan-Meier method and were assessed from the time of therapy initiation.
| R E S U L T S 3.1 | Patient characteristics
As described in Table I, patients were removed from the study, mostly due to an increase in transfusion requirements (7 out of 15 patients). Two patients were removed for worsening cytopenias, one patient for lack of response, and another patient due to an increase in marrow blasts from 3 to 12%. Two patients requested removal from the study; one of them for travel-related issues. One patient was removed due to a grade 2 neuropathy and one patient died from congestive heart failure exacerbation, which was unrelated to the study. With a median follow up of 31 months, median EFS was 3.9 months, median OS was not reached, and at 3 years 55% of the patients were alive (Supporting Information Fig- ure S1A and S1B). No correlation between response to treatment and cytogenetic and molecular genomic studies was identified.
| Toxicities
Most adverse events were grade 1 or grade 2. The different types of adverse events and their respective grade levels are detailed in Supporting Information Table SI . Three patients experienced a local reaction at the SC injection site (redness or bruising), all grade 1. Seven patients experienced neuropathy, four grade 1 and three grade 2. The latter three patients required a dose reduction of bortezomib to 1.0 mg/m 2 for persistent neuropathy. Three patients had grade 2 elevations in bilirubin levels. Three patients had grade 2 infections (febrile neutropenia, urinary tract infection, and pneumonia). Nausea, vomiting, diarrhea, fatigue, and rash also occurred in a few patients and were rated grade 1 or 2. Four patients experienced at least one grade 3 toxicity, which was attributable to bortezomib (renal dysfunction, nausea/vomiting, diarrhea, and fatigue). One patient had congestive heart failure exacerbation and another patient experienced a cerebrovascular accident;
however, these adverse events were not attributable to bortezomib.
| Correlative studies
The median pp65 level at baseline was 31% (range 7-70%), which decreased to 23% by the end of cycle 1. The pp65 level decreased by at least 10% in 7 out of 13 evaluable patients (54%, P 5 .025; Supporting Information Table SII ). This downregulation was at least a 50%
decrease from baseline in 4 out of 7 cases. In six out of 7 patients, the decrease was noted by the end of cycle 1. In the remaining patient, the decrease occurred by the end of cycle 3 (Supporting Information Table   SII ). Interestingly, 3 responders were among the 7 patients who had a decrease in pp65 level. The responders had at least a 50% reduction in pp65 level from baseline, which was noted at the end of cycle 1 in two of the patients (pp65 40%-10% and 40%-20%), and at the end of cycle 3 in one patient (pp65 25%-5%; Figure 1A and Supporting Information Figure S2 ). Clinical responses lasted between 4 and 21 weeks with a mean of 14.3 weeks. Eventual loss of response in these patients was also accompanied by an increase in pp65 level ( Figure 1A ). In the nonresponders the pp65 level was variable with no particular pattern of change: it increased in seven patients, decreased in two patients (55%-23% and 70%-5%) and remained unchanged in one patient (15%; Figure 1B and Supporting Information Figure S2 ). The remaining two non-responders had a suboptimal sample and immunofluorescence
could not be performed post-treatment.
| Cytomorphological analysis
Bone marrow characteristics are summarized in Table II . Bone marrow aspirates were reviewed to evaluate cellularity, blast count, iron (Table II and Supporting Information Figure S3 ).
In the nonresponder group (n 5 11), four patients (Patients 3, 6, 9, and 10) showed an improvement in dysplasia. One patient (Patient 10)
also had an associated decrease in pp65 level from 55% to 23%. Other patients had an increase in pp65 level or a stable level (Table II) 
| Effect on RS
Unexpectedly, we observed a decrease in the number of RS. While comparing BM samples at baseline and after treatment, a trend emerged regarding the number of RS. The majority of evaluable patients had a decrease in RS while on study. Five patients were not evaluable. Out of 10 evaluable patients who had RS assessment available at both time points, 7 patients (70%) had a significant decrease in RS count (P 5 .017). This effect was observed regardless of clinical response. Among the responders, 2 out of the 3 patients had a decrease in RS (60%-47% and 43%-30%). Among the nonresponders, 5 out of 7 evaluable patients had a decrease in RS (95%-83%, 85%-45%, 18%-1%, 6%-0%, and 60%-51%). This change was seen not only in RARS. In fact only 2 patients were classified as having RARS, both of whom were in the nonresponder group and only one of them had a decrease in RS count (95%-83%; Table II and Figure 2 ).
| DISCUSSION
Compelling data now support a deregulation of the innate immune system and inflammatory signaling in the pathogenesis of MDS. [5] [6] [7] [8] [9] [10] [11] The evidence implicates activation of TLR signaling, culminating in upregulation of the NF-jB pathway, as an important molecular mechanism in MDS. [8] [9] [10] [11] Bortezomib is a proteosomal inhibitor known to induce apoptosis of malignant hematopoietic cells, at least partly by downregulating NF-jB. [23] [24] [25] We designed this proof of concept study and tested bortezomib in low and int-1 risk MDS patients. This study differs from other studies using bortezomib in MDS in that it selectively targets patients who had evidence of NF-jB activation in their BM by using pp65 quantification as a surrogate marker. activity of bortezomib even after resistance to HMA. There was no correlation between clinical response and MDS-related molecular or cytogenetic abnormalities; however, the small number of patients limits the analysis.
From a pathologic standpoint, the findings on a cellular and molecular level were very interesting. All patients with response to bortezomib therapy had a decrease in the MDS dysplasia score. This improvement in dysplastic features was seen in megakaryocyte, granulocyte, and erythrocyte cell lines. One of the most intriguing findings is the significant decrease in RS noted in 70% of evaluable patients. This finding could be explained by the fact that the proteasome plays an important role in iron homeostasis 56, 57 that may be altered by proteasomal inhibition using bortezomib. The proteasome mediates the degradation of Iron Regulatory Proteins (IRP2 and in some cases IRP1), which play an essential role in maintaining intracellular iron balance by regulating the translation of ferritin and transferrin receptors. 58 Therefore it is reasonable to think that bortezomib could have an effect on the mitochondrial ferritin accumulation as evidenced by reduction in RS. This is a novel finding that has not been previously reported, and if confirmed in a larger patient population could have implications on the treatment of patients with RARS who harbor SF3B1 mutations using proteasome inhibitors.
The other interesting pathologic finding is the modulating effect of bortezomib on NF-jB activity. Bortezomib caused a decrease in the level of phosphorylated p65, a surrogate for NF-jB activation, in 7 out of 13 evaluable patients (54%, P 5 .025). Interestingly, significant downregulation correlated with clinical response; however, the clinical responses were short-lived and eventual loss of response correlated with increase in pp65 level. Hence, one could argue that a drug with a more potent and a more specific inhibition of the NF-jB pathway could lead to a more significant and long-lasting downregulation of pp65 and hence, could lead to a better clinical response rate. Bortezomib induces apoptosis of malignant hematopoietic cells partly through NF-jB inhibition, but it also affects many other pathways through proteosomal inhibition and therefore, is not a specific inhibitor of the NF-jB pathway.
Specific inhibitors of this pathway, notably inhibitors of IjB kinases (IKKs), are being developed with some undergoing preclinical evaluation and others already being used in clinical trials. [59] [60] [61] [62] In the future, these selective inhibitors of NF-jB could be tested for use in MDS.
In conclusion, our study provides new insights regarding what happens on a cellular and molecular level when using SC Bortezomib in lower risk MDS patients. We suggest that proteasomal inhibition could have a role in the treatment of RARS in the future. We also suggest that NF-jB activation, measured by pp65 level, could be a useful biomarker in select patients with lower-risk MDS who could benefit from therapies that target this pathway. Further studies are needed to validate these findings and to ascertain pp65 as a predictive biomarker. 
